NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Experimental Studies of the Effects of Caffeine on Glucose Regulation
Early Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2007-02-08
- Last Posted Date
- 2010-03-02
- Target Recruit Count
- 150
- Registration Number
- NCT00432887
Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma
Not Applicable
Terminated
- Conditions
- Adult GlioblastomaAdult GliosarcomaAdult Mixed GliomaAdult Anaplastic EpendymomaAdult EpendymomaAdult Giant Cell GlioblastomaAdult Pilocytic AstrocytomaAdult Pineal Gland AstrocytomaAdult Anaplastic OligodendrogliomaAdult Diffuse Astrocytoma
- Interventions
- Procedure: conventional surgeryOther: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00430079
- Locations
- 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase 2
Completed
- Conditions
- Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerFallopian Tube Cancer
- Interventions
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00429793
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Physical and Behavioral Traits of Overweight and Obese Adults
Recruiting
- Conditions
- ObesityHealthy Volunteers
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2025-06-17
- Target Recruit Count
- 2000
- Registration Number
- NCT00428987
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
HGS-ETR2 to Treat Children With Solid Tumors
Phase 1
Terminated
- Conditions
- Ewing's SarcomaOsteosarcomaNeuroblastomaRhabdomyosarcoma
- Interventions
- Drug: Interferon gamma 1b in combinationDrug: Gamma 1b potential expansion
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00428272
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
Phase 2
Terminated
- Conditions
- Adult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver Cancer
- Interventions
- Other: laboratory biomarker analysisProcedure: computed tomographyProcedure: dynamic contrast-enhanced magnetic resonance imagingOther: pharmacological study
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT00427973
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Follow-up of Breast Cancer and Multiple Myeloma Patients Previously Enrolled in NIH Gene Therapy Studies
Completed
- Conditions
- Gene Transfer
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00427726
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase 2
Completed
- Conditions
- Adult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Neoplasm
- Interventions
- Other: Pharmacological Study
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 64
- Registration Number
- NCT00423735
- Locations
- 🇺🇸
Boca Raton Regional Hospital, Boca Raton, Florida, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: Oral InsulinDrug: Placebo
- First Posted Date
- 2007-01-08
- Last Posted Date
- 2020-05-07
- Target Recruit Count
- 560
- Registration Number
- NCT00419562
- Locations
- 🇺🇸
University of Texas, Dallas, Texas, United States
🇺🇸Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇨🇦The Hospital for Sick Children, Toronto, Ontario, Canada
Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase 2
Terminated
- Conditions
- Duct Cell Adenocarcinoma of the PancreasStage IV Pancreatic CancerAcinar Cell Adenocarcinoma of the Pancreas
- Interventions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT00416793
- Locations
- 🇺🇸
MD Anderson Cancer Network, Houston, Texas, United States